Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
Tumors often consist of hypoxic regions which are resistant to chemo- and radiotherapy. Evofosfamide (also known as TH-302), a 2-nitroimidazole triggered hypoxia-activated prodrug, preferentially releases the DNA cross-linker bromo-isophosphoramide mustard in hypoxic cells. The intracellular kinase mTOR plays a key role in multiple pathways which are important in cancer progression. Here we investigated the enhanced efficacy profile and possible mechanisms of evofosfamide in combination with mTOR inhibitor (mTORi) everolimus or temsirolimus in renal cell carcinoma (RCC) xenograft models. The antitumor activities of the mTORi everolimus or temsirolimus alone, evofosfamide alone, or the combination were investigated in the 786-O and Caki-1 RCC cells in vitro and in vivo xenograft models. Two schedules were tested in which evofosfamide was started on the same day as the mTORi or 1 week after. Combination mechanisms were investigated by measuring a panel of pharmacodynamic biomarkers by immunohistochemistry. Antitumor efficacy in both RCC xenograft models was enhanced by the combination of evofosfamide and mTORi. Evofosfamide reduced the increased hypoxia induced by mTORi. Combination treatment induced increased DNA damage, decreased cell proliferation, and decreased survivin. Addition of mTORi did not change evofosfamide-mediated cytotoxicity in 786-O or Caki-1 cells in vitro which might suggest cell non-autonomous effects, specifically increased tumor hypoxia, are important for the in vivo combination activity. Taken together, evofosfamide potentiates the antitumor efficacy of mTOR inhibitors and inhibits the increased tumor hypoxia caused by mTOR inhibition. These studies provide a translational rationale for combining evofosfamide with mTOR inhibitors in clinical studies.
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Jessica D
JD
Sun
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Dharmendra
D
Ahluwalia
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Qian
Q
Liu
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Wenwu
W
Li
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Yan
Y
Wang
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Fanying
F
Meng
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Deepthi
D
Bhupathi
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Mark D
MD
Matteucci
Threshold Pharmaceuticals 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
Charles P
CP
Hart
Evofosfamide; TH-302; hypoxia-activated prodrug; mTOR inhibitor; pharmacodynamics biomarker; renal cell carcinoma; xenograft